ScholarX: LEE, HO YUN

Detailed Information

LEE, HO YUN (이호연)

Medicine (Medicine)

Research Area

Tel 02-3410-2502
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

lung adenocarcinoma:14||Radiomics:13||Computed tomography:11||Lung cancer:11||Lung adenocarcinoma:8||Prognosis:7||CT:7||Lung neoplasms:6||radiomics:6||Groundglass opacity:6||Magnetic resonance imaging:6||MRI:5||imaging:5||pathology:4||Adenocarcinoma:4||Recurrence:4||lung cancer:4||Machine learning:4||PET:4||Artificial intelligence:4||prognosis:4||computed tomography:4||heterogeneity:4||Tumor response assessment:3||Nonsmallcell lung cancer:3||COPD:3||Targeted therapy:3||Anterior mediastinum:3||Thymic cyst:3||immunotherapy:3||Biomarkers:3||Interstitial lung disease:3||Thymoma:3||Image processing:3||Guideline:3||Adenocarcinoma of lung:2||Classification:2||medical oncology:2||Deep learning:2||volumetry:2||Positron emission tomography:2||Metastasis:2||Diagnostic imaging:2||Solitary pulmonary nodule:2||Epidermal growth factor receptor:2||CT lung neoplasms:2||nonsmall cell lung cancer:2||Histology:2||nonsmall cell lung cancer:2||overall survival:2||deep learning:2||Survival:2||Survival analysis:2||NSCLC:2||dual energy CT:2||emphysema:2||Nonsmall cell lung cancer:2||Cellfree DNA:2||Immunotherapy:2||hyperprogression:2||immune checkpoint inhibitor:2||Chronic obstructive pulmonary disease:2||Tumor microenvironment:2||Quantitative imaging:2||interstitial lung disease:2||Bronchioloalveolar carcinoma:2||MDCT:2||staging:2||subtype:2||lung adenocarcinoma (ADC):2||lung neoplasms:2||artificial intelligence:2||Response criteria:2||biopsy:2||Langerhans cell histiocytosis:1||Laser cauterization:1||Liquid biopsy:1||Locally advanced nonsmall cell lung cancer:1||Logrank test:1||Longitudinal CT scans:1||Lowgrade:1||Lung:1||Lung adenocarcinoma (ADC):1||Lung cancer diagnosis:1||Lung neoplasm:1||Lung, infection:1||Lymph node metastasis:1||Lymph nodes:1||Lymphography:1||Macroscale tumor features:1||Magnetic resonance imaging (MRI):1||Martingale central limit theorem:1||Mediastinal cyst:1||Mediastinal mass:1||Metastases:1||Micropapillary:1||Mucinous:1||Mucinous adenocarcinoma:1||Multidetector Computed Tomography:1||Multimodal imaging:1||N2:1||Neoadjuvant chemoradiation:1||Neoplasm staging:1||Noncontrastenhanced chest computed tomography:1||Nonsmall cell lung:1||Nonsmall cell lung Cancer:1||Nonsmall cell lung cancer (NSCLC):1||Nonsmallcell lung carcinoma:1||Non–small cell lung cancer:1||Observer variation:1||Oncology:1||Optimal extent of pulmonary resection:1||Osimertinib:1||Otitis media with effusion:1||Outcomes:1||Outcomes assessment:1||PA2G4/EBP1:1||PET/CT:1||PRKN/PARKIN:1||PTEN protein, human:1||Parametric response mapping:1||Pecoma:1||Perfusionor patternbased CT quantification parameters:1||Perivascular epithelioid cell:1||PositronEmitted Tomography:1||Postoperative complication:1||Postoperative pulmonary complications:1||Precision medicine:1||Predictor:1||Prevascular mass:1||Primary pulmonary angiosarcoma:1||Proportional hazards model:1||Prospective studies:1||Prostate biopsy:1||Prostate cancer diagnosis:1||Pulmonary metastasectomy:1||Pulmonary mucinous cystadenocarcinoma:1||Pulmonary nodule(s):1||Pulmonary sequestration (PS):1||Pulmonary toxicity:1||Pulmonary vein stenosis:1||Pulmonary venous infarction:1||Pure ground glass opacity:1||Quantification:1||Quantitative analysis:1||Quantitative evaluation:1||Radiofrequency ablation:1||Radiotherapy:1||Receptor:1||Registration:1||Respo:1||Response Evaluation Crit:1||Rigid bronchoscopy:1||SQSTM1/p62:1||STAS:1||SUVmax:1||Size:1||Sizezone matrix features:1||Small airway disease:1||Small biopsy:1||Solidity:1||Sorafenib:1||Spread through air spaces:1||Staging:1||Subsolid nodule:1||Surgery:1||Surveillance:1||TDR:1||TNM staging:1||Targeted nextgeneration sequencing:1||Thoracic duct:1||Thorax, radiography:1||Thymic epithelial tumor:1||Thymus gland:1||Tomography:1||Tomography scanners:1||Transient asymptomatic pulmonary opacities:1||Transrectal ultrasound:1||Tuberculosis, pulmonary:1||Tumor burden:1||Tumor doubling time:1||Tumor margin:1||Tumor response:1||Tumour biomarkers:1||Tumour staging:1||Tyrosine kinase inhibitor:1||Tyrosine kinase inhibitors:1||XRay computed:1||YAP1:1||adenocarcinoma of lung:1||adult:1||atypical carcinoid:1||autoencoder:1||biomarkers:1||brain MRI:1||bronchioloalveolar carcinoma:1||bronchopneumonia:1||bronchoscopy:1||cancer:1||carcinoma, renal cell:1||chest CT scan:1||chronic obstructive pulmonary disease:1||circulating tumor DNA (ctDNA):1||computed tomography (CT):1||concurrent chemoradiation therapy:1||conditional survival:1||convolutional neural network:1||cryptogenic organizing pneumonia:1||diagnosis:1||diagnostic imaging:1||diffusion magnetic resonance imaging:1||dimensional measurement accuracy:1||droplet digital PCR:1||dual energy computed tomography (DECT):1||epidermal growth factor receptor:1||epidermal growth factor receptortyrosine kinase inhibitors (EGFRTKIs):1||followup:1||groundglass opacity:1||groundglass opacity nodule:1||haploinsufficiency:1||hepatocellular carcinoma:1||highgrade pattern:1||highthroughput nucleotide sequencing:1||histology:1||image:1||immune checkpoint inhibitor (ICI):1||incidentally detected pulmonary nodule:1||influenza A (H1N1):1||integrated positron emission tomography/computed tomography:1||interstitial lung abnormalities:1||interstitial pneumonia:1||intratumor heterogeneity:1||intratumoral heterogeneity:1||kidney:1||lowdose CT screening:1||lung CT:1||lung cancer response:1||lung interstitial disease:1||lung neoplasm:1||lung nodule:1||lymph node:1||lymph node metastasis:1||machine learning:1||magnetic r:1||magnetic resonance imaging:1||management guidelines:1||micropapillary:1||mitophagy:1||molecular subtype:1||molecular targeted therapy:1||mucinous:1||multidetector computed tomography:1||multimodal analysis:1||natural course:1||neoplasm staging:1||neoplasms:1||nomogram:1||nonsmall cell lung cancer (NSCLC):1||observer variation:1||perfusion scintigraphy:1||phenotype:1||plasma:1||pneumonia:1||pneumonitis:1||positron emission tomography:1||positron emission tomography/computed tomography:1||positron emission tomography/magnetic resonance imaging:1||ALK:1||predicted postoperative (PPO) lung function:1||predictive model:1||predictor:1||pregnancy:1||prognosi:1||prognostic biomarker:1||progressive pulmonary fibrosis:1||pseudomesotheliomatous manifestation:1||pulmonary fibrosis:1||pulmonary function imaging:1||pulmonary function test:1||pulmonary lymphangitic carcinomatosis:1||pure groundglass nodule:1||quantitative analysis:1||quantitative image variables:1||quantitative imaging analysis:1||radial EBUS:1||radiation pneumonitis:1||recurrence:1||resection:1||response evaluation criteria in solid tumors:1||segment counting:1||severity of illness:1||small cell lung cancer:1||smoking:1||solitary pulmonary nodule:1||spread through air spaces:1||statistical data analysis:1||survival:1||survival analysis,therapeutic chemoembolization:1||survival outcome:1||survival rate:1||symptom:1||texture analysis:1||tumor doubling time:1||tumor infiltrating lymphocyte (TIL):1||tumor margin:1||tumor microenvironment:1||tyrosine kinase inhibitor:1||ultrashort echotime MRI:1||ultrasound:1||ventilation flowweighted map:1||ventilationweighted map:1||precision oncology:1||Adenocarcinoma, mucinous:1||Adrenal:1||Allergy:1||Anaplastic lymphoma kinase (ALK):1||Bone metastases:1||Bronchoscopy:1||CT scan of chest:1||Cancer detection:1||Carcinoma:1||Chronic obstructive pulmonary disease (COPD):1||Chylothorax:1||Cigarette smoking:1||Clear cell:1||Clinical stage IA nonsmall cell lung cancer:1||Clustering analysis:1||Colorectal cancer:1||Complications:1||Computed tomography (CT), highresolution:1||Computed tomography scans:1||Computed xray tomography:1||Consolidationtotumor ratio:1||Cystic mass:1||DECT:1||DILD:1||Delta method:1||Diffuse interstitial lung disease:1||Diffusion weight:1||Dlco:1||Drugassociated interstitial lung disease:1||Dualenergy CT:1||Dynamic contrastenhanced CT:1||EGFR mutation:1||EGFRTKI:1||EGFRmutation:1||Elderly patients:1||Embolization, therapeutic:1||Emphysema:1||Endobronchial inflammatory myofibroblastic tumor:1||Endoscopic resection:1||Eosinophilic granuloma:1||Epidermal growth factor:1||Epidermal growth factor receptor (EGFR):1||Erlotinib:1||F18FDG PET/CT:1||Feature reproducibility:1||Fieller method:1||Followup:1||Followup CT scan:1||Gefitinib:1||Groundglass nodule:1||Guideline for multicenter analysis:1||Guideline, Nonsmall cell lung cancer:1||Hazard rate:1||Heterogeneity:1||Highgrade pattern:1||Highresolution CT (HRCT):1||Highresolution computed tomography:1||Histiocytosis x:1||Histogram analysis:1||ICI:1||IPF/UIP:1||Imaging:1||Immune checkpoint inhibitors:1||Institutional decisionmaking algorithm:1||Intratumour heterogeneity:1||Invasive mediastinal nodal staging:1||Invasive mucinous adenocarcinoma:1||Iodine quantification:1||Ischemia:1||KaplanMeier estimator:1||Kirsten rat sarcoma viral oncogene homolog (KRAS):1||Krebs von den Lungen6:1||Langerhans cell:1||

STATISTICS: Total View:; Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE